Innoviva Inc. (INVA) — closed signal from May 10, 2026
Partial Published before the outcome was known, scored automatically when the window closed on August 8, 2026.
Predicted vs. what happened
INVA price · publication thesis → realized outcomesplit-adjusted
$22.00 – $23.20Entry zone — fair-value band
$22.89Published — price the day we called it
$27.93Target — the price the thesis aimed for
$24.17Peak — highest point inside the window, not a realized return
$20.51Window close — end-of-window price, context only
What happened
Partial
Reached 25% of the predicted growth at its peak, without hitting the target.
Peak price
$24.17
peak on June 24, 2026 — not a realized returnPeak gain
+5.6%
peak, from the publication priceWindow close
$20.51
end-of-window price, context onlyDays to target
—
Window
May 10, 2026 – August 8, 2026
The thesis — published May 10, 2026
Predicted growth
+22%
over the measurement windowTarget price
$27.93
the price the thesis aimed forEntry zone
$22.00 – $23.20
the fair-value band we waited forPrice at publication
$22.89
published May 10, 2026Confidence
76%
how strongly the data lined upTimeframe
Short-term (0–3 months)
Innoviva earns steady cash from drug royalties and has a solid balance sheet. Recent research notes stronger royalty prospects, which could prompt investors to reassess the stock in the next few months. Trading is thin and price momentum isn't confirmed yet, so upside depends on renewed market interest rather than new trials.
Primary drivers
- Regular royalty payments create steady, high-margin cash flow
- Recent research pointed to stronger-than-expected royalty prospects
- Strong balance sheet lowers the chance of needing extra funding
- Low current valuation could rise if investor interest returns
Prices are shown split- and dividend-adjusted, matching what public charts show today.
Lyra
Read the next call before it closes.
This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.